Barclays’s Dogwood Therapeutics DWTX Stock Holding History

Barclays’s Portfolio DWTX Stock Details DWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$253	Buy	+157	New	+$260	﹤0.01%	5081
2025 Q4	–	Sell	-5	Closed	-$39	–	5801
2025 Q3	$39	Buy	+5	New	+$25	﹤0.01%	5329

Other funds holding DWTX

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Barclays's DWTX Position: Q2 2026 in Review

Barclays opened a new position in Dogwood Therapeutics (DWTX) in Q2 2026: 157 shares worth $253. The stake represents ﹤0.01% of the portfolio and ranks #5081 among its holdings. This is a return to the name: Barclays previously reported a position in DWTX as recently as Q3 2025.

Barclays first reported a position in DWTX in Q3 2025 and has held it in 2 quarters since. 15 funds tracked by Wall St. Rank hold DWTX as of Q2 2026.

Barclays held 157 shares of Dogwood Therapeutics worth $253 as of Q2 2026.
Dogwood Therapeutics was a new Barclays position in Q2 2026.
Dogwood Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5081 holding.
Barclays first reported a position in Dogwood Therapeutics in Q3 2025 and has held it in 2 quarters since.
15 funds tracked by Wall St. Rank held Dogwood Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.